Cm Management, LLC Rigel Pharmaceuticals Inc Transaction History

Cm Management, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	BUY	$1.12 - $1.57 $336,000 - $471,000	300,000 Added 17.65%	2,000,000 $2.96 Million
Q4 2023 Feb 12, 2024	BUY	$0.72 - $1.56 $144,000 - $312,000	200,000 Added 13.33%	1,700,000 $2.47 Million
Q4 2022 Feb 09, 2023	BUY	$0.67 - $11.9 $134,000 - $2.38 Million	200,000 Added 15.38%	1,500,000 $2.25 Million
Q2 2022 Aug 08, 2022	BUY	$0.67 - $3.19 $351,750 - $1.67 Million	525,000 Added 67.74%	1,300,000 $1.47 Million
Q4 2021 Feb 02, 2022	BUY	$2.36 - $3.57 $59,000 - $89,250	25,000 Added 3.33%	775,000 $2.05 Million
Q2 2021 Aug 10, 2021	BUY	$3.09 - $4.54 $772,500 - $1.14 Million	250,000 Added 50.0%	750,000 $3.26 Million
Q1 2021 May 12, 2021	BUY	$3.35 - $4.93 $335,000 - $493,000	100,000 Added 25.0%	500,000 $1.71 Million
Q4 2020 Feb 04, 2021	BUY	$2.35 - $3.74 $940,000 - $1.5 Million	400,000 New	400,000 $1.4 Million

334K

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

Get notified when there are updates to the investment portfolio of Cm Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Cm Management, LLC with notifications on news.